Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 05:00 ET | Source: Levicept

Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis

In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with osteoarthritis (OA) A significant correlation...
September 25, 2025 04:00 ET | Source: Levicept

Levicept to Present Key New Data from Phase II Trial of LEVI-04, a Novel Neurotrophin-3 Inhibitor, at ACR Convergence 2025

A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients with osteoarthritisChanges in bone marrow lesion area were...
June 12, 2025 03:00 ET | Source: Levicept

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritisRapid onset of action observedImprovement in function out of proportion to...
April 26, 2025 04:00 ET | Source: Levicept

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis

Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all dosesSignificant improvement in all signs and symptoms of osteoarthritis for all dosesPoster...
November 14, 2024 10:00 ET | Source: Levicept

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, for Treatment of Patients with Moderate to Severe Osteoarthritis at ACR Convergence 2024

Primary efficacy endpoint met – significant analgesia across all dosesSignificant improvement in all signs and symptoms of osteoarthritis for all dosesWell tolerated with no increase in incidence of...
October 28, 2024 05:00 ET | Source: Levicept

Levicept to Present Phase II Data at ACR Convergence 2024

SANDWICH, United Kingdom, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, today...
August 06, 2024 03:00 ET | Source: Levicept

Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, for the Treatment of Patients with Moderate to Severe Osteoarthritis

All primary and secondary efficacy endpoints met – significant analgesia across all measures for all dosesWell tolerated with no increase in incidence of rapid joint deterioration compared to...
December 13, 2023 04:00 ET | Source: Levicept

Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04

SANDWICH, United Kingdom, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications,...
November 30, 2023 04:00 ET | Source: Levicept

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE)...